Core-binding factor acute myeloid leukemia in first relapse: A retrospective study from the French AML Intergroup

Blood

Volumn 124, Issue 8, 2014, Pages 1312-1319

  Hospital, Marie Anne ^a   Prebet, Thomas ^b   Bertoli, Sarah ^c   Thomas, Xavier ^d   Tavernier, Emmanuelle ^e   Braun, Thorsten ^f   Pautas, Cécile ^g   Perrot, Aurore ^h   Lioure, Bruno ⁱ   Rousselot, Philippe ^j   Tamburini, Jér̂ome ^k   Cluzeau, Thomas ^l   Konopacki, Johanna ^m   Randriamalala, Edouard ⁿ   Berthon, Céline ^o   Gourin, Marie Pierre ^p   Recher, Christian ^c   Cahn, Jean Yves ^q   Ifrah, Norbert ^r   Dombret, Hervé ^a   Boissel, Nicolas ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CHU PURPAN   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Institut de Cancerologie de la Loire   (France)

^f AVICENNE HOSPITAL   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j CENTRE HOSPITALIER DE VERSAILLES   (France)

^k Institut Cochin   (France)

^l UNIVERSITY HOSPITAL OF NICE   (France)

^m PERCY MILITARY HOSPITAL   (France)

ⁿ POITIERS UNIVERSITY HOSPITAL   (France)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p LIMOGES UNIVERSITY HOSPITAL   (France)

^q HÔPITAL MICHALLON   (France)

^r ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CORE BINDING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TRISOMY 8; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN; CORE BINDING FACTORS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84907326228     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-549212     Document Type: Article

References (31)

1. Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004;23(24):4297-4307. (Pubitemid 38758595)
2. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24):4255-4262. (Pubitemid 38758592)
3. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
4. Grimwade D, Walker H, Oliver F, et al; The Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
5. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173-4179. (Pubitemid 28440576)
6. Byrd JC, Dodge RK, Carroll A, et al. Patients with t (8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767-3775.
7. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-1094. (Pubitemid 41095042)
8. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol. 2009;16(2):92-97.
9. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
10. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99(10):3517-3523. (Pubitemid 34534517)
11. Delaunay J, Vey N, Leblanc T, et al; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille- Toulouse cooperative groups. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462-469.
12. de Labarthe A, Pautas C, Thomas X, et al; Acute Leukemia French Association. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. Bone Marrow Transplant. 2005;35(8):767-773. (Pubitemid 40626698)
13. Gorin NC, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(19):3183-3188.
14. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31(10):1293-1301.
15. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750. (Pubitemid 41102131)
16. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705-5717.
17. Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-2223.
18. Paschka P, Döhner K. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematology (Am Soc Hematol Educ Program). 2013;2013(1):209-219.
19. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808-814.
20. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011;118(7):1754-1762.
21. Lioure B, Béné MC, Pigneux A, et al; GOELAMS. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood. 2012;119(12):2943-2948.
22. Mantel NBD, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81-86.
23. Hospital MA, Thomas X, Castaigne S, et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplant. 2012;47(11):1436-1441.
24. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35-44. (Pubitemid 14142275)
25. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
26. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100-1120.
27. Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
28. Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-970. (Pubitemid 43797286)
29. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-1978. (Pubitemid 46211376)
30. Bornhäuser M, Illmer T, Oelschlaegel U, et al. Gemtuzumab ozogamicin as part of reducedintensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin Cancer Res. 2008;14(17):5585-5593.
31. Wang ES, Zeidan A, Tan W, et al. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2012;53(10):2085-2088.